The invention relates to Orai1-dependent selective capacitative calcium entry inhibitors as well as to the therapeutic use thereof.

The invention relates to Orai1-dependent selective capacitative calcium entry inhibitors as well as to the therapeutic use thereof.

The present application relates to large-scale methods of uniformly coating packaging surfaces with a benzoxaborole compound.

The present application relates to large-scale methods of uniformly coating packaging surfaces with a benzoxaborole compound.

The present disclosure provides certain bicyclic heteroaryl compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. In some embodiments, the bicyclic heteroaryl compounds includes those of Formula (I). Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

##STR00001##

The present disclosure provides certain bicyclic heteroaryl compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. In some embodiments, the bicyclic heteroaryl compounds includes those of Formula (I). Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

##STR00001##

The present application relates to methods for treatment of bacteria and viruses with C.sub.2-C.sub.7 alkyl boronic acids to reduce growth and virulence.

The present application relates to methods for treatment of bacteria and viruses with C.sub.2-C.sub.7 alkyl boronic acids to reduce growth and virulence.

Disclosed are potent immuno-DASH inhibitors and their use in the treatment of cell proliferative diseases.

Disclosed are potent immuno-DASH inhibitors and their use in the treatment of cell proliferative diseases.